Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,12560443,duration,"In addition, the mean duration of grade 4 neutropenia was similar in both groups (2.8 and 2.4 days, respectively).","Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12560443/),d,2.8,20431,DB00019,Pegfilgrastim
,12560443,duration,"In addition, the mean duration of grade 4 neutropenia was similar in both groups (2.8 and 2.4 days, respectively).","Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12560443/),d,2.4,20432,DB00019,Pegfilgrastim
,17235504,absolute neutrophil nadir,Median absolute neutrophil nadir was 0.32 g/l on day 9.,Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17235504/),[g] / [l],0.32,32738,DB00019,Pegfilgrastim
,17235504,trough plasma level,Median pegfilgrastim trough plasma level was 0.43 ng/ml on the day preceding the next application.,Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17235504/),[ng] / [ml],0.43,32739,DB00019,Pegfilgrastim
,17545847,area under the curve (AUC),Chemotherapy-naïve patients with locally advanced or metastatic NSCLC were treated with carboplatin area under the curve (AUC) 6 mg/ml per minute intravenously on day 1 and vinorelbine 30 mg/m2 intravenously on days 1 and 8 every 3 weeks for four planned cycles.,A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17545847/),[mg] / [min·ml],6,36914,DB00019,Pegfilgrastim
,17545847,Overall response rate,Overall response rate was 27%.,A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17545847/),%,27,36915,DB00019,Pegfilgrastim
,17545847,survival,Median survival was 9.4 months (95% confidence interval: 6.1-18.0) with a 3-year survival rate of 20%.,A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17545847/),month,9,36916,DB00019,Pegfilgrastim
≥,22991919,time to recovery to an absolute neutrophil count,"Pharmacokinetic parameters and neutrophil-related values for duration of neutropenia, neutrophil nadir, time to recovery to an absolute neutrophil count ≥500/μL or ≥2000/μL, and days of antibiotic support were determined.","Pegfilgrastim administered in an abbreviated schedule, significantly improved neutrophil recovery after high-dose radiation-induced myelosuppression in rhesus macaques. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22991919/),,500,54709,DB00019,Pegfilgrastim
,25672916,MTDs,The MTDs for buparlisib were 100 mg/day in Group 1 and 80 mg/day in Group 2.,Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25672916/),[mg] / [d],100,91206,DB00019,Pegfilgrastim
,25672916,MTDs,The MTDs for buparlisib were 100 mg/day in Group 1 and 80 mg/day in Group 2.,Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25672916/),[mg] / [d],80,91207,DB00019,Pegfilgrastim
,25672916,objective response rate,"Among 25 patients with measurable disease, the confirmed objective response rate was 20% (one complete response, four partial responses).",Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25672916/),%,20,91208,DB00019,Pegfilgrastim
,19920107,apparent clearance,Pegfilgrastim apparent clearance (11 mL/h/kg) was similar to that reported in adults.,Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19920107/),[ml] / [h·kg],11,98475,DB00019,Pegfilgrastim
,18524995,C(max),No discernable correlation between pharmacokinetic parameter values and degree of renal impairment was observed; the mean values ranged from 147 to 201 ng/mL for C(max) and from 7469 to 8513 ng x h/mL for AUC.,Pharmacokinetics and pharmacodynamics of pegfilgrastim in subjects with various degrees of renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18524995/),[ng] / [ml],147 to 201,100304,DB00019,Pegfilgrastim
,18524995,AUC,No discernable correlation between pharmacokinetic parameter values and degree of renal impairment was observed; the mean values ranged from 147 to 201 ng/mL for C(max) and from 7469 to 8513 ng x h/mL for AUC.,Pharmacokinetics and pharmacodynamics of pegfilgrastim in subjects with various degrees of renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18524995/),[h·ng] / [ml],7469 to 8513,100305,DB00019,Pegfilgrastim
,12123336,duration of,"Mean duration of grade 4 neutropenia in cycle 1 was 2.7,2 and 1.3 days for doses of pegfilgrastim, and 1.6 days for filgrastim.",Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123336/),d,2.7,109481,DB00019,Pegfilgrastim
,12123336,duration of,"Mean duration of grade 4 neutropenia in cycle 1 was 2.7,2 and 1.3 days for doses of pegfilgrastim, and 1.6 days for filgrastim.",Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123336/),d,2,109482,DB00019,Pegfilgrastim
,12123336,duration of,"Mean duration of grade 4 neutropenia in cycle 1 was 2.7,2 and 1.3 days for doses of pegfilgrastim, and 1.6 days for filgrastim.",Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123336/),d,1.3,109483,DB00019,Pegfilgrastim
,12123336,duration of,"Mean duration of grade 4 neutropenia in cycle 1 was 2.7,2 and 1.3 days for doses of pegfilgrastim, and 1.6 days for filgrastim.",Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123336/),d,1.6,109484,DB00019,Pegfilgrastim
,16982322,Peak levels,Peak levels were reached at day +4 (94 ng/mL; range: 37-205) and were maintained until day +7 (85 ng/mL; range: 35-186).,Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16982322/),[ng] / [ml],94,115134,DB00019,Pegfilgrastim
,16982322,Peak levels,Peak levels were reached at day +4 (94 ng/mL; range: 37-205) and were maintained until day +7 (85 ng/mL; range: 35-186).,Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16982322/),[ng] / [ml],85,115135,DB00019,Pegfilgrastim
,16982322,time to neutrophil reconstitution,"Comparison with the control group without G-CSF support showed that time to neutrophil reconstitution was significantly shorter in the pegfilgrastim group with 10 vs 15 days, respectively (p < 0.001).",Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16982322/),d,10,115136,DB00019,Pegfilgrastim
,16982322,time to neutrophil reconstitution,"Comparison with the control group without G-CSF support showed that time to neutrophil reconstitution was significantly shorter in the pegfilgrastim group with 10 vs 15 days, respectively (p < 0.001).",Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16982322/),d,15,115137,DB00019,Pegfilgrastim
,28281183,overall objective response rate,The overall objective response rate was 14% (2 /14).,A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28281183/),%,14,135265,DB00019,Pegfilgrastim
,32567217,area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-t ),"The mean area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-t ) and the mean maximum concentration (Cmax ) of PEG-rhG-CSF after treatment A were 5070 ng·h/mL and 125 ng/mL, respectively; these values were comparable to those measured after treatment B (5340 ng·h/mL and 123 ng/mL, respectively).","Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32567217/),[h·ng] / [ml],5070,137540,DB00019,Pegfilgrastim
,32567217,area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-t ),"The mean area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-t ) and the mean maximum concentration (Cmax ) of PEG-rhG-CSF after treatment A were 5070 ng·h/mL and 125 ng/mL, respectively; these values were comparable to those measured after treatment B (5340 ng·h/mL and 123 ng/mL, respectively).","Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32567217/),[h·ng] / [ml],5340,137541,DB00019,Pegfilgrastim
,32567217,area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-t ),"The mean area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-t ) and the mean maximum concentration (Cmax ) of PEG-rhG-CSF after treatment A were 5070 ng·h/mL and 125 ng/mL, respectively; these values were comparable to those measured after treatment B (5340 ng·h/mL and 123 ng/mL, respectively).","Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32567217/),[ng] / [ml],123,137542,DB00019,Pegfilgrastim
,32567217,maximum concentration (Cmax ),"The mean area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-t ) and the mean maximum concentration (Cmax ) of PEG-rhG-CSF after treatment A were 5070 ng·h/mL and 125 ng/mL, respectively; these values were comparable to those measured after treatment B (5340 ng·h/mL and 123 ng/mL, respectively).","Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32567217/),[ng] / [ml],125,137543,DB00019,Pegfilgrastim
,32567217,maximum concentration (Cmax ),"The mean area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-t ) and the mean maximum concentration (Cmax ) of PEG-rhG-CSF after treatment A were 5070 ng·h/mL and 125 ng/mL, respectively; these values were comparable to those measured after treatment B (5340 ng·h/mL and 123 ng/mL, respectively).","Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32567217/),[ng] / [ml],123,137544,DB00019,Pegfilgrastim
,32567217,area under the △ANC,"The mean value of area under the △ANC (baseline-adjusted ANC)-time curve and the maximum △ANC values were 4380 × 109 h/L and 33.1 × 109 /L, respectively, in the treatment A group, and 5170 × 109 h/L and 38.6 × 109 /L, respectively, in the treatment B group.","Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32567217/),[h] / [l],4380 ×,137545,DB00019,Pegfilgrastim
,32567217,area under the △ANC,"The mean value of area under the △ANC (baseline-adjusted ANC)-time curve and the maximum △ANC values were 4380 × 109 h/L and 33.1 × 109 /L, respectively, in the treatment A group, and 5170 × 109 h/L and 38.6 × 109 /L, respectively, in the treatment B group.","Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32567217/),[h] / [l],5170,137546,DB00019,Pegfilgrastim
,32567217,maximum △ANC,"The mean value of area under the △ANC (baseline-adjusted ANC)-time curve and the maximum △ANC values were 4380 × 109 h/L and 33.1 × 109 /L, respectively, in the treatment A group, and 5170 × 109 h/L and 38.6 × 109 /L, respectively, in the treatment B group.","Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32567217/),,33.1 ×,137547,DB00019,Pegfilgrastim
,32567217,maximum △ANC,"The mean value of area under the △ANC (baseline-adjusted ANC)-time curve and the maximum △ANC values were 4380 × 109 h/L and 33.1 × 109 /L, respectively, in the treatment A group, and 5170 × 109 h/L and 38.6 × 109 /L, respectively, in the treatment B group.","Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32567217/),[109] / [l],38.6,137548,DB00019,Pegfilgrastim
,25894719,AUC0-inf,"Pegfilgrastim mean AUC0-inf values for the on-body injector (n = 125) and manual injection (n = 128) were 10,900 and 11,100 h ng/mL, respectively; mean C max values were 248 and 262 ng/mL, respectively.",Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25894719/),[h·ng] / [ml],"10,900",155034,DB00019,Pegfilgrastim
,25894719,AUC0-inf,"Pegfilgrastim mean AUC0-inf values for the on-body injector (n = 125) and manual injection (n = 128) were 10,900 and 11,100 h ng/mL, respectively; mean C max values were 248 and 262 ng/mL, respectively.",Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25894719/),[h·ng] / [ml],"11,100",155035,DB00019,Pegfilgrastim
,25894719,C max,"Pegfilgrastim mean AUC0-inf values for the on-body injector (n = 125) and manual injection (n = 128) were 10,900 and 11,100 h ng/mL, respectively; mean C max values were 248 and 262 ng/mL, respectively.",Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25894719/),[ng] / [ml],248,155036,DB00019,Pegfilgrastim
,25894719,C max,"Pegfilgrastim mean AUC0-inf values for the on-body injector (n = 125) and manual injection (n = 128) were 10,900 and 11,100 h ng/mL, respectively; mean C max values were 248 and 262 ng/mL, respectively.",Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25894719/),[ng] / [ml],262,155037,DB00019,Pegfilgrastim
,24962521,maximum tolerated dose,The maximum tolerated dose was identified as 24 mg/m(2) due to dose-limiting thrombocytopenia in two patients receiving 30 mg/m(2) .,"Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962521/),[mg] / [m(2],24,168431,DB00019,Pegfilgrastim
,21723892,half-life,Simultaneous pharmacokinetic analysis of released and encapsulated G-CSF plasma levels showed that the G-CSF release occurs with the first-order kinetics and the half-life is 4.8h.,Prolonged circulation and in vivo efficacy of recombinant human granulocyte colony-stimulating factor encapsulated in polymeric micelles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21723892/),h,4.8,184996,DB00019,Pegfilgrastim
,31497882,objective response rate,The objective response rate was 31%; median PFS was 14.1 months (95% confidence interval [CI]: 7.1 and 22.2); and OS was 18.6 months (95% CI: 11.8 and 22.2).,"Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31497882/),%,31,196141,DB00019,Pegfilgrastim
,31497882,PFS,The objective response rate was 31%; median PFS was 14.1 months (95% confidence interval [CI]: 7.1 and 22.2); and OS was 18.6 months (95% CI: 11.8 and 22.2).,"Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31497882/),month,14.1,196142,DB00019,Pegfilgrastim
,31497882,OS,The objective response rate was 31%; median PFS was 14.1 months (95% confidence interval [CI]: 7.1 and 22.2); and OS was 18.6 months (95% CI: 11.8 and 22.2).,"Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31497882/),month,18.6,196143,DB00019,Pegfilgrastim
,26668251,time to ANC recovery,"Between-group efficacy parameters were comparable except for time to ANC recovery in cycle 1 (40 mg of balugrastim, 2.0 days; 50 mg of balugrastim, 2.1; pegfilgrastim, 2.6).",A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26668251/),d,2.0,208259,DB00019,Pegfilgrastim
,26668251,time to ANC recovery,"Between-group efficacy parameters were comparable except for time to ANC recovery in cycle 1 (40 mg of balugrastim, 2.0 days; 50 mg of balugrastim, 2.1; pegfilgrastim, 2.6).",A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26668251/),,2,208260,DB00019,Pegfilgrastim
,26668251,terminal elimination half-life,"Median terminal elimination half-life was ≈37 hours for 40 mg of balugrastim, ≈36 for 50 mg of balugrastim, and ≈45 for pegfilgrastim.",A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26668251/),h,37,208261,DB00019,Pegfilgrastim
,26668251,terminal elimination half-life,"Median terminal elimination half-life was ≈37 hours for 40 mg of balugrastim, ≈36 for 50 mg of balugrastim, and ≈45 for pegfilgrastim.",A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26668251/),,36,208262,DB00019,Pegfilgrastim
,26668251,terminal elimination half-life,"Median terminal elimination half-life was ≈37 hours for 40 mg of balugrastim, ≈36 for 50 mg of balugrastim, and ≈45 for pegfilgrastim.",A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26668251/),,45,208263,DB00019,Pegfilgrastim
<,19395467,absolute neutrophil counts,Eighteen Japanese lung cancer patients who had experienced severe neutropenia (absolute neutrophil counts <0.5 x 10(9) cells/l) were enrolled.,A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19395467/),,0.5 x,212909,DB00019,Pegfilgrastim
> or =,14692520,time to absolute neutrophil count (ANC) recovery,"The pharmacokinetics of pegfilgrastim were characterized and the duration of grade 4 neutropenia, time to absolute neutrophil count (ANC) recovery to > or = 2.0 x 10(9)/l, neutrophil nadir, and incidence of febrile neutropenia were determined in the first 21-day chemotherapy cycle.",Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14692520/),,2.0 x 10(9),234938,DB00019,Pegfilgrastim
,14692520,duration of grade 4 neutropenia,The incidence of grade 4 neutropenia in cycle 1 was 43% with a mean (SD) duration of grade 4 neutropenia value of 1.0 (1.4) day.,Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14692520/),d,1.0,234939,DB00019,Pegfilgrastim
,14692520,time to ANC recovery,"The median [quartiles] time to ANC recovery was 10 [9, 11] days.",Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14692520/),d,10,234940,DB00019,Pegfilgrastim
,14692520,terminal half-life,"After the second peak, concentration of pegfilgrastim declined linearly with a median terminal half-life of approximately 42 h.",Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14692520/),h,42,234941,DB00019,Pegfilgrastim
,29318653,systemic half-lives,The systemic half-lives of filgrastim (2.6 h) and pegfilgrastim (10.1 h) were as expected.,Pharmacokinetic-pharmacodynamic modelling of neutrophil response to G-CSF in healthy subjects and patients with chemotherapy-induced neutropenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29318653/),h,2.6,240835,DB00019,Pegfilgrastim
,29318653,systemic half-lives,The systemic half-lives of filgrastim (2.6 h) and pegfilgrastim (10.1 h) were as expected.,Pharmacokinetic-pharmacodynamic modelling of neutrophil response to G-CSF in healthy subjects and patients with chemotherapy-induced neutropenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29318653/),h,10.1,240836,DB00019,Pegfilgrastim
,29318653,half-life,"The effective half-life of chemotherapy was 9.6 h, with a 2-day killing effect.",Pharmacokinetic-pharmacodynamic modelling of neutrophil response to G-CSF in healthy subjects and patients with chemotherapy-induced neutropenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29318653/),h,9.6,240837,DB00019,Pegfilgrastim
,22337718,Total clearance,Total clearance was 9.43 mL/h and Vd(ss) was 9.61 l.,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),[ml] / [h],9.43,266008,DB00019,Pegfilgrastim
,22337718,Vd(ss),Total clearance was 9.43 mL/h and Vd(ss) was 9.61 l.,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),l,9.61,266009,DB00019,Pegfilgrastim
,22337718,clearance,Rituximab clearance was reduced (8.21 mL/h vs 12.68 mL/h; P = .003) and elimination half-life was prolonged in women compared with men (t(1/2β) = 30.7 vs 24.7 days; P = .003).,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),[ml] / [h],8.21,266010,DB00019,Pegfilgrastim
,22337718,clearance,Rituximab clearance was reduced (8.21 mL/h vs 12.68 mL/h; P = .003) and elimination half-life was prolonged in women compared with men (t(1/2β) = 30.7 vs 24.7 days; P = .003).,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),[ml] / [h],12.68,266011,DB00019,Pegfilgrastim
,22337718,t(1/2β),Rituximab clearance was reduced (8.21 mL/h vs 12.68 mL/h; P = .003) and elimination half-life was prolonged in women compared with men (t(1/2β) = 30.7 vs 24.7 days; P = .003).,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),d,30.7,266012,DB00019,Pegfilgrastim
,22337718,t(1/2β),Rituximab clearance was reduced (8.21 mL/h vs 12.68 mL/h; P = .003) and elimination half-life was prolonged in women compared with men (t(1/2β) = 30.7 vs 24.7 days; P = .003).,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),d,24.7,266013,DB00019,Pegfilgrastim
